Company: SHPH
Filing Date: 2025-03-13
Form Type: 424B3
Source: 0001493152-25-010109
Chunk: 21

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-03-13
Form: 424B3
Chunk 21
---
 and the risk factors discussed in the sections entitled “Risk Factors” contained in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as may be amended, supplemented or superseded from time to time by other reports we file with the SEC and incorporated by reference in this prospectus, together with all of the other information contained in this prospectus. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or this prospectus or any additional risks and uncertainties actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you might lose all or part of your investment.

Risks Related to this Offering

Sales of substantial amounts of our securities in the public market could depress the market price of our common stock.

Our common stock is listed for trading on the Nasdaq Capital Market. If our stockholders sell substantial amounts of our common stock in the public market, or the market perceives that such sales may occur, the market price of our securities could fall and we may be unable to sell our securities in the future.

Our securities may experience extreme price and volume fluctuations, which could lead to costly litigation for us and make an investment in us less appealing.

The market price of our common stock may fluctuate substantially due to a variety of factors, including:

| ● | the                                                                  
 status and results of our clinical trials for our product candidate; |

| ● | our                                                                                                                                
 ability to fund and complete our study and, if such study provides data supporting an FDA submission, our ability to apply for and 
 obtain clearance from the FDA;                                                                                                     |

| ● | our                                         
 ability to remain a going concern;          |
| ● | our ability to maintain our Nasdaq listing; |

| ● | our                          
 business strategy and plans; |

| ● | the                                                                           
 potential market for our product candidate, if approved for sale in the U.S.; |

| ● | new                                                                                                
 regulatory pronouncements and changes in regulatory guidelines and timing of regulatory approvals; |

| ● | general                                    
 and industry-specific economic conditions; |

| ● | variations                                                                                                                   
 in our quarterly financial and operating results, including the rate at which we incur negative cash flow in future periods; |

| ● | additions                              
 to or departures of our key personnel; |

| ● | changes                                                                                           
 in